Firefly Neuroscience, Inc. (AIFF)

Firefly Neuroscience, Inc. (AIFF) Technology Profile & Competitive Position

Firefly Neuroscience, Inc. develops and provides neuroscientific software solutions, leveraging AI for the diagnosis and treatment of mental illnesses and neurological disorders. Their Brain Network Analytics platform targets pharmaceutical companies and medical practitioners, positioning them in the evolving landscape of AI-driven healthcare technology.

What Is the Investment Thesis for AIFF?

Firefly Neuroscience, Inc. presents a compelling investment thesis centered on its Brain Network Analytics platform and its potential to disrupt the mental health and neurological disorder diagnostics market. The company's focus on AI-driven solutions offers a unique value proposition to both pharmaceutical companies and medical practitioners. With a market capitalization of $19.78M, Firefly Neuroscience is positioned for growth if it can successfully commercialize and scale its technology. Key catalysts include expanding its customer base, securing partnerships with major pharmaceutical companies, and demonstrating improved patient outcomes through clinical studies. However, the company's negative profit margin of -1741.0% and a beta of 1.93 indicate high risk and volatility. The company's ability to manage its cash flow and achieve profitability will be critical to its long-term success.

Based on FMP financials and quantitative analysis

AIFF Key Highlights

• Market Cap of $19.78M indicates a small-cap company with potential for high growth but also higher risk.
• Gross Margin of 56.5% suggests a strong pricing power and efficient cost management in its core operations.
• Profit Margin of -1741.0% highlights significant challenges in achieving profitability, requiring close monitoring of expenses and revenue generation.
• Beta of 1.93 indicates higher volatility compared to the market, suggesting the stock price may fluctuate more significantly.
• Focus on Brain Network Analytics positions the company in a niche market with potential for growth in the mental health and neurological disorder diagnostics sector.

Who Are AIFF's Competitors?

AIFF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AIFF's Key Strengths?

• Proprietary Brain Network Analytics software.
• Focus on AI-driven solutions for mental health.
• Potential for improved patient outcomes.
• Serves both pharmaceutical companies and medical practitioners.

What Are AIFF's Weaknesses?

• Negative profit margin.
• Small market capitalization.
• Limited number of employees.
• High beta indicating volatility.

What Could Drive AIFF Stock Higher?

• Potential FDA approval for Brain Network Analytics.
• Expansion of partnerships with pharmaceutical companies.
• Development of new AI-driven diagnostic tools.
• Increasing adoption of telehealth platforms.

What Are the Key Risks for AIFF?

• Financial-distress signal — its Altman Z-Score of -12.02 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-94.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competition from established medical device companies.
• Regulatory hurdles and compliance requirements.
• Technological obsolescence.
• Negative profit margin and financial instability.

What Are the Growth Opportunities for AIFF?

• Expansion into New Geographies: Firefly Neuroscience has the opportunity to expand its market reach beyond its current base. By targeting new geographic regions with unmet needs in mental health diagnostics, the company can increase its customer base and revenue streams. The global market for mental health software is projected to reach $3.8 billion by 2027, offering a significant opportunity for growth. Timeline: 1-3 years.
• Strategic Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to integrate Brain Network Analytics into drug development and clinical trials can provide Firefly Neuroscience with access to valuable data and resources. These partnerships can also lead to the development of new diagnostic tools and treatment strategies. The pharmaceutical industry spends billions annually on research and development, making it a lucrative market for innovative technologies. Timeline: 1-2 years.
• Development of New AI-Driven Diagnostic Tools: Investing in research and development to create new AI-driven diagnostic tools for a wider range of mental illnesses and neurological disorders can expand Firefly Neuroscience's product portfolio and market reach. The company can leverage its existing expertise in Brain Network Analytics to develop solutions for conditions such as Alzheimer's disease, Parkinson's disease, and autism spectrum disorder. Timeline: 2-4 years.
• Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA can enhance the credibility and market acceptance of Brain Network Analytics. Regulatory approvals can also open up new opportunities for reimbursement and adoption by healthcare providers. The regulatory landscape for medical devices and software is complex, but securing approvals can provide a significant competitive advantage. Timeline: 1-3 years.
• Leveraging Telehealth Platforms: Integrating Brain Network Analytics with telehealth platforms can enable remote monitoring and diagnosis of mental health conditions, expanding access to care and improving patient outcomes. The telehealth market is experiencing rapid growth, driven by increasing demand for remote healthcare services and advancements in technology. This integration can provide Firefly Neuroscience with a new channel for reaching patients and healthcare providers. Timeline: 1-2 years.

What Opportunities Does AIFF Have?

• Expansion into new geographic markets.
• Strategic partnerships with pharmaceutical companies.
• Development of new AI-driven diagnostic tools.
• Integration with telehealth platforms.

What Threats Does AIFF Face?

• Competition from established medical device companies.
• Regulatory hurdles and compliance requirements.
• Technological obsolescence.
• Economic downturn affecting healthcare spending.

What Are AIFF's Competitive Advantages?

• Proprietary AI algorithms for Brain Network Analytics.
• Specialized expertise in neuroscientific solutions.
• Established relationships with pharmaceutical companies and medical practitioners.
• First-mover advantage in the application of AI to mental health diagnostics.

What Does AIFF Do?

Firefly Neuroscience, Inc. is a medical technology and artificial intelligence company dedicated to improving outcomes for patients suffering from mental illnesses and neurological disorders. The company was founded to address the growing need for advanced diagnostic and treatment tools in the fields of mental health and cognitive disorders. Its primary offering, Brain Network Analytics, is a software platform designed to aid in the diagnosis and treatment of conditions such as depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder (ADHD). Firefly Neuroscience serves both pharmaceutical companies and medical practitioners, providing them with tools to enhance their understanding and treatment of neurological and mental health conditions. The company's focus on artificial intelligence allows for the development of sophisticated algorithms and analyses that can identify patterns and insights that may not be readily apparent through traditional diagnostic methods. Headquartered in Kenmore, CA, Firefly Neuroscience operates with a team of 13 employees, reflecting its current stage as a developing technology company in the healthcare sector.

What Products and Services Does AIFF Offer?

• Develops Brain Network Analytics software.
• Provides diagnostic tools for mental illnesses.
• Offers treatment solutions for neurological disorders.
• Utilizes artificial intelligence for data analysis.
• Serves pharmaceutical companies.
• Serves medical practitioners.
• Focuses on conditions like depression, dementia, and ADHD.

How Does AIFF Make Money?

• Software as a Service (SaaS) model for Brain Network Analytics.
• Revenue generated through subscriptions and licensing fees.
• Partnerships with pharmaceutical companies for research and development.
• Direct sales to medical practitioners and healthcare organizations.

What Industry Does AIFF Operate In?

Firefly Neuroscience operates within the rapidly evolving medical technology and AI sector. The industry is characterized by increasing demand for advanced diagnostic and treatment solutions for mental illnesses and neurological disorders. The market for AI-driven healthcare solutions is experiencing substantial growth, driven by advancements in technology and increasing awareness of mental health issues. Competition includes established medical device companies, as well as emerging AI-focused startups. Firefly Neuroscience's success depends on its ability to differentiate its Brain Network Analytics platform and establish strategic partnerships within the healthcare ecosystem.

Who Are AIFF's Key Customers?

• Pharmaceutical companies involved in drug development for mental illnesses and neurological disorders.
• Medical practitioners, including psychiatrists, neurologists, and primary care physicians.
• Hospitals and clinics specializing in mental health and neurological care.
• Research institutions conducting studies on brain function and mental health.

Company Profile

Firefly Neuroscience, Inc. operates in the Software - Application industry within the Technology sector. It is headquartered in Kenmore, CA. The company is led by CEO Greg Lipschitz. AIFF has traded publicly since 2002.

ROE -95%Key Financial Metrics

Return on equity for Firefly Neuroscience, Inc. stands at -94.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -82.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -31.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -34.9%, the inverse of the P/E and a quick read on earnings relative to price.

AIFF Valuation & Market Position

With a $19.78M market cap, Firefly Neuroscience, Inc. sits in the micro-cap segment of the market. Relative to its peer group, AIFF's quantitative score of 52/100 is below the peer average of 68/100.

Quarterly Financial Performance: Firefly Neuroscience, Inc.

Revenue for Firefly Neuroscience, Inc. came in at $485K during Q1 2026, a 17.7% improvement versus the preceding quarter. The company recorded a net loss of $2.0M, with diluted EPS of $-0.13. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Technology company. Across the four most recent quarters, AIFF averaged $-0.17 in diluted EPS.

F-Score 2/9Financial Health

Firefly Neuroscience, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.02 places it in the distress zone, a signal of elevated financial risk.

AIFF Financials

AIFF Latest News

AIFF Analyst Consensus

AIFF MoonshotScore

AIFF Technology Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources